Inist to jointly develop oral ‘bazedoxifene/cholecalciferol’ combination drug

Published: 2017-09-12 13:47:41

Updated: 2017-09-12 13:47:41

Inist Bio Pharmaceutical(CEO Kook-Hyun Kim) will conduct an open innovation service of its product based on its know-hows as a CMO(contract manufacturing organization).

The company will open a briefing to suggest joint development of a bazedoxifene/cholecalciferol combination drug being developed by the company’s headquarters at 2pm on the 14^th of September.

The bazedoxifene substance, an ost...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.